₹103 per tablet, while Glenmark has the first-mover advantage. But the revenue potential of the drug depends on the infection rate and the adoption of the drug as a treatment."This appears to be a one time opportunity only for covid times.
Multiple players are set to launch the product over the next 12 months given that there are no patents in India," said Anshuman Gupta, pharma analyst, Investec Securities.As such, the revenue potential is expected to decrease once competition kicks in.
Read more on livemint.com